Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 22 Results

Intervention Indication Therapeutic Area Year Actions
IMCgp100 for the Treatment of Advanced or Metastatic Uveal Melanoma IMCgp100 (Tebentafusp) Uveal melanoma Oncology 2017 View  |  Download
Larotrectinib (LOXO-101) for advanced solid cancers [with an NTRK1, NTRK2, or NTRK3 gene fusion] Larotrectinib (LOXO-101; Viktravi; larotrectinib sulfate) Solid tumours Haematological Cancer and Lymphomas , Oncology 2017 View  |  Download
Nivolumab in combination with ipilimumab for cisplatin-ineligible patients with untreated, unresectable or metastatic urothelial cancer– first line Ipilimumab (Yervoy; BMS 734016; MDX 101) , Nivolumab (Opdivo; BMS-936558; ONO-4538) Bladder cancer Oncology , Urological Cancer 2021 View  |  Download
Pembrolizumab for Stage IV Colorectal Carcinoma – first line Pembrolizumab (Keytruda; MK-3475) Colorectal cancer Gastrointestinal Cancer , Oncology 2018 View  |  Download
Pembrolizumab for treatment of solid tumours – second line Pembrolizumab (Keytruda; MK-3475) Solid tumours Haematological Cancer and Lymphomas , Oncology 2021 View  |  Download
Pembrolizumab with lenvatinib for previously treated metastatic colorectal cancer Lenvatinib (Kisplyx; E7080; lenvatinib mesilate) , Pembrolizumab (Keytruda; MK-3475) Colorectal cancer Gastroenterology , Oncology 2022 View  |  Download
Pexidartinib for tenosynovial giant cell tumour Pexidartinib (PLX3397) Tenosynovial giant cell tumour (TGCT) Oncology 2019 View  |  Download
Pralsetinib for treating thyroid cancer Pralsetinib (BLU-667; Gavreto) Thyroid cancer Oncology 2021 View  |  Download
Selpercatinib for advanced thyroid cancer with RET alterations Selpercatinib (LOXO-292; LY3527723) Medullary thyroid cancer (MTC) , Thyroid cancer Head and Neck Cancer , Oncology 2019 View  |  Download
Selpercatinib for previously untreated advanced RET-fusion positive thyroid cancer Selpercatinib (LOXO-292; LY3527723) Thyroid cancer Oncology 2022 View  |  Download
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications